0.00Open0.00Pre Close0 Volume0 Open Interest54.00Strike Price0.00Turnover8554.61%IV-23.24%PremiumNov 1, 2024Expiry Date16.35Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9847Delta0.0044Gamma4.57Leverage Ratio-197.1675Theta0.0000Rho4.50Eff Leverage0.0000Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet